First Time Loading...

Henan Lingrui Pharmaceutical Co Ltd
SSE:600285

Watchlist Manager
Henan Lingrui Pharmaceutical Co Ltd Logo
Henan Lingrui Pharmaceutical Co Ltd
SSE:600285
Watchlist
Price: 24.85 CNY -0.84% Market Closed
Updated: May 18, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

4.6B
+7%
Assets
Growth Rates:
1 Year
+13%
3 Years
+37%
5 Years
+38%
7 Years
+51%
10 Years
+190%
1.9B
+7%
Liabilities
Growth Rates:
1 Year
+16%
3 Years
+73%
5 Years
+54%
7 Years
+93%
10 Years
+199%
2.7B
+7%
Equity
Growth Rates:
1 Year
+11%
3 Years
+19%
5 Years
+28%
7 Years
+31%
10 Years
+185%

Balance Sheet Decomposition
Henan Lingrui Pharmaceutical Co Ltd

4.6B
Assets
1.9B
Liabilities
4.6B
Assets
1.9B
Liabilities
Current Assets 2.4B
Cash & Short-Term Investments 1.2B
Receivables 657.6m
Other Current Assets 570.7m
Non-Current Assets 2.2B
Long-Term Investments 362.2m
PP&E 659.5m
Intangibles 241.9m
Other Non-Current Assets 922m
Current Liabilities 1.8B
Accounts Payable 75m
Accrued Liabilities 142.4m
Short-Term Debt 101.8m
Other Current Liabilities 1.5B
Non-Current Liabilities 82.6m
Long-Term Debt 6.1m
Other Non-Current Liabilities 76.5m

Balance Sheet
Henan Lingrui Pharmaceutical Co Ltd

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2013 Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022
Assets
Cash & Cash Equivalents
442
371
415
378
340
639
741
0
801
1 179
Cash
1
0
0
0
0
1
0
0
801
1 179
Cash Equivalents
442
370
415
378
339
639
741
0
0
0
Short-Term Investments
8
19
20
13
10
9
28
57
421
276
Total Receivables
175
159
200
344
579
569
663
717
441
533
Accounts Receivables
10
9
29
30
218
187
173
146
173
196
Other Receivables
166
151
171
314
361
382
491
571
268
337
Inventory
162
223
298
484
365
324
287
331
428
486
Other Current Assets
52
49
31
344
324
54
36
811
40
34
Total Current Assets
840
821
964
1 563
1 617
1 595
1 754
1 917
2 131
2 508
PP&E Net
450
491
608
783
851
819
809
772
787
745
PP&E Gross
450
491
608
783
851
819
809
772
787
745
Accumulated Depreciation
156
140
167
209
220
273
326
403
462
525
Intangible Assets
183
167
182
183
319
310
303
283
286
242
Goodwill
8
8
8
1
1
1
1
0
0
0
Long-Term Investments
138
954
999
367
413
278
334
350
456
677
Other Long-Term Assets
30
33
73
86
106
108
116
137
133
172
Other Assets
8
8
8
1
1
1
1
0
0
0
Total Assets
1 648
N/A
2 475
+50%
2 833
+14%
2 982
+5%
3 308
+11%
3 110
-6%
3 316
+7%
3 458
+4%
3 793
+10%
4 344
+15%
Liabilities
Accounts Payable
40
55
59
62
85
58
68
79
78
68
Accrued Liabilities
50
56
69
89
96
100
108
538
611
938
Short-Term Debt
326
439
390
205
285
280
281
166
296
182
Current Portion of Long-Term Debt
20
25
22
0
0
0
0
0
2
1
Other Current Liabilities
138
185
348
402
543
504
557
284
452
523
Total Current Liabilities
573
759
888
757
1 009
943
1 014
1 066
1 438
1 712
Long-Term Debt
25
0
40
20
0
0
0
0
8
6
Deferred Income Tax
1
96
105
42
35
17
27
21
18
29
Minority Interest
18
17
19
25
30
12
11
9
8
8
Other Liabilities
64
59
55
51
60
56
55
48
43
39
Total Liabilities
681
N/A
931
+37%
1 107
+19%
894
-19%
1 133
+27%
1 028
-9%
1 106
+8%
1 145
+4%
1 514
+32%
1 793
+18%
Equity
Common Stock
357
536
536
592
592
586
568
568
568
567
Retained Earnings
327
350
438
695
823
978
1 185
1 340
1 481
1 665
Additional Paid In Capital
290
125
168
565
565
474
340
320
272
310
Treasury Stock
0
0
0
0
0
38
0
0
98
68
Other Equity
7
534
584
234
193
82
117
85
56
77
Total Equity
967
N/A
1 544
+60%
1 726
+12%
2 087
+21%
2 174
+4%
2 082
-4%
2 210
+6%
2 313
+5%
2 279
-1%
2 551
+12%
Total Liabilities & Equity
1 648
N/A
2 475
+50%
2 833
+14%
2 982
+5%
3 308
+11%
3 110
-6%
3 316
+7%
3 458
+4%
3 793
+10%
4 344
+15%
Shares Outstanding
Common Shares Outstanding
536
536
536
592
592
586
568
568
554
559

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 138,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.